Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 Summary GlobalData's clinical trial report, 'Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012" provides data on the Focal Segmental Glomerulosclerosis (FSGS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Focal Segmental Glomerulosclerosis (FSGS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Focal Segmental Glomerulosclerosis (FSGS). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials
Review, H2, 2012
Published on November 2012
Report Summary
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, 'Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012" provides data
on the Focal Segmental Glomerulosclerosis (FSGS) clinical trial scenario. This report provides elemental information and data relating
to the clinical trials on Focal Segmental Glomerulosclerosis (FSGS). It includes an overview of the trial numbers and their recruitment
status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their
phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for
treating Focal Segmental Glomerulosclerosis (FSGS). This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and
Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Focal Segmental Glomerulosclerosis (FSGS) 6
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 1/6

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by BRIC Nations 15
Clinical Trials by G7 Nations 16
Clinical Trials in G7 Nations by Trial Status 17
Clinical Trials by E7 Nations 18
Clinical Trials in E7 Nations by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Unaccomplished Trials of Focal Segmental Glomerulosclerosis (FSGS) 23
Subjects Recruited Over a Period of Time 26
Prominent Sponsors 27
Top Companies Participating in Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials 29
Prominent Drug Comparison 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Genzyme Corporation 31
Clinical Trial Overview of Genzyme Corporation 31
Retrophin, LLC 32
Clinical Trial Overview of Retrophin, LLC 32
FibroGen, Inc. 33
Clinical Trial Overview of FibroGen, Inc. 33
Clinical Trial Overview of Top Universities / Institutes / Hospitals 34
Nanjing University 34
Clinical Trial Overview of Nanjing University 34
Xi'an Jiaotong University College of Medicine 35
Clinical Trial Overview of Xi'an Jiaotong University College of Medicine 35
University of Tsukuba 36
Clinical Trial Overview of University of Tsukuba 36
Children's Research Institute 37
Clinical Trial Overview of Children's Research Institute 37
Guangdong General Hospital 38
Clinical Trial Overview of Guangdong General Hospital 38
Ruijin Hospital 39
Clinical Trial Overview of Ruijin Hospital 39
University Medical Centre Ljubljana 40
Clinical Trial Overview of University Medical Centre Ljubljana 40
Nanjing Medical University 41
Clinical Trial Overview of Nanjing Medical University 41
Columbia University 42
Clinical Trial Overview of Columbia University 42
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 2/6

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
University of Sao Paulo 43
Clinical Trial Overview of University of Sao Paulo 43
New York University School of Medicine 44
Clinical Trial Overview of New York University School of Medicine 44
Sunnybrook Health Sciences Centre 45
Clinical Trial Overview of Sunnybrook Health Sciences Centre 45
Stanford University 46
Clinical Trial Overview of Stanford University 46
Five Key Clinical Profiles 47
Appendix 73
Abbreviations 73
Definitions 73
Research Methodology 75
Secondary Research 75
About GlobalData 76
Contact Us 76
Disclaimer 76
Source 77
List of Tables
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Zone, 2012* 7
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 8
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 9
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2012* 10
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Europe, Top Countries, 2012* 11
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, North America, Top Countries, 2012* 12
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2012* 13
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Central and South America, Top Countries, 2012* 14
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, BRIC Countries, 2012* 15
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, G7 Countries, 2012* 16
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 17
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, E7 Countries, 2012* 18
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 19
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Phase, 2012* 20
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials In Progress by Phase 2012* 21
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 22
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Suspended Clinical Trials, 2012* 23
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Withdrawn Clinical Trials, 2012* 24
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Terminated Clinical Trials, 2012* 25
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2006-2011 26
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 28
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 29
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 30
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Genzyme Corporation,
2012* 31
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Retrophin, LLC, 2012* 32
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by FibroGen, Inc., 2012* 33
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 3/6

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nanjing University, 2012*
34
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Xi'an Jiaotong University
College of Medicine, 2012* 35
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Tsukuba,
2012* 36
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Research
Institute, 2012* 37
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Guangdong General
Hospital, 2012* 38
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ruijin Hospital, 2012* 39
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Medical Centre
Ljubljana, 2012* 40
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nanjing Medical University,
2012* 41
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2012*
42
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo,
2012* 43
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York University
School of Medicine, 2012* 44
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sunnybrook Health
Sciences Centre, 2012* 45
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2012*
46
List of Figures
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Zone (%), 2012* 7
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 8
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 9
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2012* 10
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Europe, Top Countries (%), 2012* 11
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, North America, Top Countries (%), 2012* 12
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, BRIC Countries (%), 2012* 15
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, G7 Countries (%), 2012* 16
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 17
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, E7 Countries (%), 2012* 18
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 19
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Phase (%), 2012* 20
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2012* 21
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 22
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2006-2011 26
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 27
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 29
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 30
GlobalData Methodology 75
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 4/6

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 2 500.00 Quantity: _____
Site License--USD 5 000.00 Quantity: _____
Corporate License--USD 7 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 5/6

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012 (From Slideshare) Page 6/6